HR Execs on the Move

Maruho Medical

www.maruho-medical.com

 
We are focused on improving sports medicine outcomes by providing innovative technologies and supporting surgeons with integrity, collaboration, and a commitment to excellence. We achieve this by providing medical devices and services that are unique, highly effective, reliable, easy to learn and cost-effective. At present, maruho medical offers a comprehensive portfolio of orthopedic surgery products that complement arthroscopic shoulder, knee, hip, and extremity procedures.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.maruho-medical.com
  • 3005 Chastain Meadows Parkway NW Suite 300
    Marietta, GA USA 30066
  • Phone: 888.404.3980

Executives

Name Title Contact Details
Bret Schwartzhoff
Senior Vice President of Sales and Marketing Profile

Similar Companies

Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.

Tioga Pharmaceuticals Inc

Tioga Pharmaceuticals Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Serve You

Serve You is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Curie Therapeutics

Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie`s radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads. Curie`s mission is to revolutionize the use of radiomedicines in cancer.

XTuit

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.